Advanced Materials · 2025 · 14 citations · 20 references
MedicineOncologyPharmacologyImmunotherapyNanoparticle Drug DeliveryTumor MicroenvironmentCancer ImmunotherapyImmunotherapy For Genitourinary CancersMtor Inhibitor TherapyProstate CancerTargeted Cancer TherapyTargeted TherapyDrug Efflux MechanismsImmunosuppressive FunctionPi3k InhibitorsProstate Cancer ImmunotherapyProstate Immune MicroenvironmentProstate-specific Antigen - Targeted TherapyProstate-specific Membrane Antigen TargetingPsma-targeted Therapy
Acquired drug resistance and the immunosuppressive tumor microenvironment significantly limit the efficacy of chemotherapy and immunotherapy in advanced prostate cancer. Blocking the PI3K/mTOR signaling pathway has been recently proved as a new strategy to improve sensitivity to chemotherapy and immunotherapy. Herein, glutathione (GSH)-sensitive nanoparticles (PSMA-NP/BEZ) are developed that can target prostate-specific membrane antigen (PSMA), loaded with PI3K/mTOR dual inhibitor prodrug BEZ235. BEZ235 can be released from PSMA-NP/BEZ in response to elevated GSH levels in prostate cancer tissues, inhibiting the PI3K/AKT/mTOR pathway and impairing downstream cellular functions such as cell proliferation, DNA repair, and protein synthesis. When combined with paclitaxel, PSMA-NP/BEZ could reduce drug efflux by downregulating P-glycoprotein expression in cancer cells, thus enhancing the sensitivity to chemotherapy. Furthermore, PSMA-NP/BEZ could impair the immunosuppressive functions of myeloid-derived suppressor cells and reshape the "cold" immune microenvironment in prostate cancer, enhancing immunotherapeutic efficacy and including long-term immune memory against tumor recurrence. PSMA-NP/BEZ serves a safe and promising strategy to improve the efficacy of chemotherapy and immunotherapy in advanced prostate cancer.
20
The Cancer Genome Atlas: Creating Lasting Value beyond Its Data
Carolyn M. Hutter, Jean C. Zenklusen · Cell · 2018 · 933 citations · Full text
Effective combinatorial immunotherapy for castration-resistant prostate cancer
Xin Lü, James W. Horner, Erin Paul et al. · Nature · 2017 · 547 citations · Full text